As we demonstrated here, SF3B1 mutation activates the mTOR pathway through alternative splicing of Nfatc1, linking SF3B1 mutation, BCR signaling, and the mTOR pathway in CLL and providing potential therapeutic options specific to the disease context. This evidence concerns the gene SF3B1 and B-cell chronic lymphocytic leukemia.